Bausch + Lomb Corporation (BLCO) News
Filter BLCO News Items
BLCO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BLCO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BLCO News From Around the Web
Below are the latest news stories about BAUSCH & LOMB CORP that investors may wish to consider to help them evaluate BLCO as an investment opportunity.
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. […] |
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising ChallengeVAUGHAN, Ontario, January 07, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to curing glaucoma, are launching the second annual "Faces of Glaucoma" campaign. The campaign, which will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide,1 will take place throughout Glau |
Bausch + Lomb price target lowered to $22 from $25 at Evercore ISIEvercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source f |
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceVAUGHAN, Ontario, January 02, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET |
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chancesInvesting.com -- Bank of America has reinstated coverage of Bausch + Lomb Corp (NYSE:BLCO) with an "underperform" rating and a price target of $18, amid reduced prospects of a private equity buyout. |
Bausch + Lomb Responds to Rumors of a Potential SaleVAUGHAN, Ontario, December 12, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): |
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment CapabilitiesVAUGHAN, Ontario, December 11, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without |
Bausch & Lomb Corporation (BLCO)-A Bull Case TheoryIn this article, we’ll summarize a bullish thesis posted on VIC covering Bausch & Lomb Corporation (BLCO) in late July when BLCO stock was trading at $15.83. Currently, BLCO stock is trading at $19.68, which is near its 52-week high of $21.69. So, BLCO stock has gained over 24% since the publication of this thesis. […] |
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling ProgramsVAUGHAN, Ontario, November 14, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United States. That’s equivalent to the weight of roughly 690 polar bears1. |
Bausch + Lomb Third Quarter 2024 Earnings: Beats ExpectationsBausch + Lomb ( NYSE:BLCO ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.20b (up 19% from 3Q 2023... |